Promising drug combo aims to slow advanced prostate cancer
NCT ID NCT05171816
First seen Nov 20, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This study tests whether adding olaparib to standard abiraterone therapy can delay cancer growth or death in men with metastatic castration-resistant prostate cancer who have not yet had chemotherapy. About 110 participants receive either olaparib plus abiraterone or a placebo plus abiraterone. The main goal is to see how long it takes for the cancer to progress or for death to occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Beijing, 100034, China
-
Research Site
Beijing, 100050, China
-
Research Site
Beijing, 100142, China
-
Research Site
Beijing, 100191, China
-
Research Site
Beijing, 100730, China
-
Research Site
Chongqing, 400038, China
-
Research Site
Guangzhou, 510180, China
-
Research Site
Guangzhou, 510515, China
-
Research Site
Guizhou, 550002, China
-
Research Site
Henan, 450008, China
-
Research Site
Hubei, 430030, China
-
Research Site
Hunan, 410008, China
-
Research Site
Hunan, 410013, China
-
Research Site
Jilin, 130012, China
-
Research Site
Jilin, 130021, China
-
Research Site
Liaoning, 110001, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nanjing, 2100008, China
-
Research Site
Ningbo, 315000, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Sichuan, 610041, China
-
Research Site
Sichuan, 610072, China
-
Research Site
Xi'an, 710061, China
-
Research Site
Zhejiang, 310009, China
-
Research Site
Zhejiang, 310014, China
Conditions
Explore the condition pages connected to this study.